RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RAPT · as of Sep 30, 2025
Ownership Breakdown
66
Institutional Holders
▲ 15 vs Q2
$351.34M
Total Inst. Value
▲ $215.73M vs Q2
16.54M
Shares Outstanding
freeFloat 50.60%
13.62M
13F Shares Held
▼ 3.34M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RAPT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 1.64M | 6.07% | 6.07% | $42.20B | Nov 17, 2025 | — held |
FORESITE CAPITAL MANAGEMENT VI LLC pharmaceutical preparations | 1.56M | 5.79% | 5.79% | $40.30B | Nov 14, 2025 | — held |
RTW INVESTMENTS, LP pharmaceutical preparations | 1.47M | 5.45% | 5.45% | $37.92B | Nov 14, 2025 | — held |
ORBIMED ADVISORS LLC pharmaceutical preparations | 1.09M | 4.03% | 4.03% | $28.02B | Nov 14, 2025 | ▼ 555.3K |
BOONE CAPITAL MANAGEMENT LLC pharmaceutical preparations | 782.5K | 2.90% | 2.90% | $20.18B | Nov 14, 2025 | NEW |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 751.4K | 2.79% | 2.79% | $19.38B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 696.2K | 2.58% | 2.58% | $17.95B | Nov 7, 2025 | ▼ 183.9K |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 623.3K | 2.31% | 2.31% | $16.07B | Nov 14, 2025 | ▼ 328.3K |
IKARIAN CAPITAL, LLC pharmaceutical preparations | 615.0K | 2.28% | 2.28% | $15.86B | Nov 14, 2025 | NEW |
SIREN, L.L.C. pharmaceutical preparations | 580.5K | 2.15% | 2.15% | $14.97B | Nov 13, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
9
Increased
+363.6K shares20
New Positions
first time holders14
Decreased
−1.66M shares0
Sold Out
fully exitedNet shares change (top 50)
1.30M
+363.6K / −1.66M
Net new holders
+15
20 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RAPT insider trading · insider activity
Source: SEC Form 4
6
Buy transactions
62
Sell transactions
0.10
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lyons-Williams Lori director | Mar 3, 2026 | U-Tender | 4,956 | — | — | 0 | Form 4 ↗ |
Lyons-Williams Lori director | Mar 3, 2026 | D-Return | 2,813 | $306.24 | $861.5K | 0 | Form 4 ↗ |
Lyons-Williams Lori director | Mar 3, 2026 | D-Return | 1,063 | $109.12 | $116.0K | 0 | Form 4 ↗ |
Lyons-Williams Lori director | Mar 3, 2026 | D-Return | 1,618 | $167.44 | $270.9K | 0 | Form 4 ↗ |
Lyons-Williams Lori director | Mar 3, 2026 | D-Return | 4,561 | $37.04 | $168.9K | 0 | Form 4 ↗ |
Lyons-Williams Lori director | Mar 3, 2026 | D-Return | 32,229 | $7.44 | $239.8K | 0 | Form 4 ↗ |
GRAY MARY ANN director | Mar 3, 2026 | U-Tender | 4,956 | — | — | 0 | Form 4 ↗ |
GRAY MARY ANN director | Mar 3, 2026 | D-Return | 2,813 | $220.24 | $619.5K | 0 | Form 4 ↗ |
GRAY MARY ANN director | Mar 3, 2026 | D-Return | 498 | $170.16 | $84.7K | 0 | Form 4 ↗ |
GRAY MARY ANN director | Mar 3, 2026 | D-Return | 938 | $226.16 | $212.1K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
RAPT Therapeutics, Inc. (RAPT) is primarily owned by institutional investors, who hold approximately 82.4% of total shares outstanding. Company insiders own approximately 49.40%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of RAPT Therapeutics, Inc. is TCG CROSSOVER MANAGEMENT, LLC, holding approximately 1.64 million shares — equal to 6.07% of outstanding shares — as of September 30, 2025.
A total of 66 institutional investors currently hold RAPT stock, with a combined institutional value of approximately $351,342,799 as of the most recent 13F filing period.
Frequently asked questions
RAPT ownershipRAPT Therapeutics, Inc. (RAPT) is primarily owned by institutional investors, who hold approximately 82.4% of shares. The largest shareholder is TCG CROSSOVER MANAGEMENT, LLC with a 6.07% stake. Company insiders hold 49.40%. Data sourced from SEC Form 13F as of September 30, 2025.